KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Depreciation & Amortization (CF): 2009-2025

Historic Depreciation & Amortization (CF) for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Sep 2025 value amounting to $9.9 million.

  • Jazz Pharmaceuticals' Depreciation & Amortization (CF) rose 27.05% to $9.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year increase of 35.08%. This contributed to the annual value of $32.8 million for FY2024, which is 7.70% up from last year.
  • Jazz Pharmaceuticals' Depreciation & Amortization (CF) amounted to $9.9 million in Q3 2025, which was down 17.03% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $11.9 million during Q2 2025, and its lowest value of $4.8 million during Q1 2021.
  • For the 3-year period, Jazz Pharmaceuticals' Depreciation & Amortization (CF) averaged around $8.7 million, with its median value being $7.8 million (2024).
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first soared by 61.60% in 2021, then fell by 2.99% in 2023.
  • Jazz Pharmaceuticals' Depreciation & Amortization (CF) (Quarterly) stood at $7.3 million in 2021, then increased by 0.23% to $7.3 million in 2022, then grew by 4.14% to $7.6 million in 2023, then grew by 24.40% to $9.5 million in 2024, then climbed by 27.05% to $9.9 million in 2025.
  • Its Depreciation & Amortization (CF) was $9.9 million in Q3 2025, compared to $11.9 million in Q2 2025 and $10.4 million in Q1 2025.